Literature DB >> 33682631

Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice.

Karthik Ravi1, Andrea Franson1, Morgan J Homan2, Holly Roberts1, Manjunath P Pai2, Zachary Miklja3, Miao He2, Bo Wen2, Lydia L Benitez2, Anthony J Perissinotti2, Dale L Bixby4, Carl Koschmann1, Bernard L Marini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33682631      PMCID： PMC8855457          DOI： 10.1080/10428194.2021.1894647

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  18 in total

1.  Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.

Authors:  Sotirios G Papageorgiou; Vasiliki Pappa; Christina Economopoulou; Panagiotis Tsirigotis; Frida Konsioti; Eleni-Dikaia Ionnidou; Spyros Chondropoulos; Diamantina Vasilatou; Efstathios Papageorgiou; Theofanis Economopoulos; John Dervenoulas
Journal:  Leuk Res       Date:  2010-04-14       Impact factor: 3.156

2.  Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.

Authors:  Ferdinando Frigeri; Manuela Arcamone; Luigia Luciano; Raffaele Di Francia; Fabrizio Pane; Antonio Pinto
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

3.  Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma.

Authors:  Zachary Miklja; Viveka Nand Yadav; Rodrigo T Cartaxo; Ruby Siada; Chase C Thomas; Jessica R Cummings; Brendan Mullan; Stefanie Stallard; Alyssa Paul; Amy K Bruzek; Kyle Wierzbicki; Tao Yang; Taylor Garcia; Ian Wolfe; Marcia Leonard; Patricia L Robertson; Hugh Jl Garton; Daniel R Wahl; Hemant Parmar; Jann N Sarkaria; Cassie Kline; Sabine Mueller; Theodore Nicolaides; Chana Glasser; Sarah Es Leary; Sriram Venneti; Chandan Kumar-Sinha; Arul M Chinnaiyan; Rajen Mody; Manjunath P Pai; Timothy N Phoenix; Bernard L Marini; Carl Koschmann
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

4.  Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

Authors:  Joseph M Gozgit; Matthew J Wong; Lauren Moran; Scott Wardwell; Qurish K Mohemmad; Narayana I Narasimhan; William C Shakespeare; Frank Wang; Tim Clackson; Victor M Rivera
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

5.  Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

Authors:  Jurjen S Lagas; Robert A B van Waterschoot; Vicky A C J van Tilburg; Michel J Hillebrand; Nienke Lankheet; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Authors:  Kimmo Porkka; Perttu Koskenvesa; Tuija Lundán; Johanna Rimpiläinen; Satu Mustjoki; Richard Smykla; Robert Wild; Roger Luo; Montserrat Arnan; Benoit Brethon; Lydia Eccersley; Henrik Hjorth-Hansen; Martin Höglund; Hana Klamova; Håvar Knutsen; Suhag Parikh; Emmanuel Raffoux; Franz Gruber; Finella Brito-Babapulle; Hervé Dombret; Rafael F Duarte; Erkki Elonen; Ron Paquette; C Michel Zwaan; Francis Y F Lee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

Review 7.  Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

Authors:  Sandra W Cowan-Jacob; Valerie Guez; Gabriele Fendrich; James D Griffin; Doriano Fabbro; Pascal Furet; Janis Liebetanz; Jürgen Mestan; Paul W Manley
Journal:  Mini Rev Med Chem       Date:  2004-03       Impact factor: 3.862

Review 8.  Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.

Authors:  Maria Ilaria Del Principe; Luca Maurillo; Francesco Buccisano; Giuseppe Sconocchia; Mariagiovanna Cefalo; Giovanna De Santis; Ambra Di Veroli; Concetta Ditto; Daniela Nasso; Massimiliano Postorino; Marco Refrigeri; Cristina Attrotto; Giovanni Del Poeta; Francesco Lo-Coco; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

9.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.

Authors:  Antoine Daina; Olivier Michielin; Vincent Zoete
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

10.  Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients.

Authors:  Armin Sebastian Guntner; Andreas Peyrl; Lisa Mayr; Bernhard Englinger; Walter Berger; Irene Slavc; Wolfgang Buchberger; Johannes Gojo
Journal:  Acta Neuropathol Commun       Date:  2020-06-03       Impact factor: 7.801
View more
  1 in total

Review 1.  Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.

Authors:  Kallen Schwark; Dana Messinger; Jessica R Cummings; Joshua Bradin; Abed Kawakibi; Clarissa M Babila; Samantha Lyons; Sunjong Ji; Rodrigo T Cartaxo; Seongbae Kong; Evan Cantor; Carl Koschmann; Viveka Nand Yadav
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.